School of Biological and Health Systems Engineering, Arizona State University, Tempe, AZ, USA.
School of Biological and Health Systems Engineering, Arizona State University, Tempe, AZ, USA.
Adv Drug Deliv Rev. 2024 Feb;205:115161. doi: 10.1016/j.addr.2023.115161. Epub 2023 Dec 22.
Autoimmune diseases are a diverse and complex set of chronic disorders with a substantial impact on patient quality of life and a significant global healthcare burden. Current approaches to autoimmune disease treatment comprise broadly acting immunosuppressive drugs that lack disease specificity, possess limited efficacy, and confer undesirable side effects. Additionally, there are limited treatments available to restore organs and tissues damaged during the course of autoimmune disease progression. Cell therapies are an emergent area of therapeutics with the potential to address both autoimmune disease immune dysfunction as well as autoimmune disease-damaged tissue and organ systems. In this review, we discuss the pathogenesis of common autoimmune disorders and the state-of-the-art in cell therapy approaches to (1) regenerate or replace autoimmune disease-damaged tissue and (2) eliminate pathological immune responses in autoimmunity. Finally, we discuss critical considerations for the translation of cell products to the clinic.
自身免疫性疾病是一组多样且复杂的慢性疾病,对患者的生活质量有重大影响,并给全球医疗保健带来巨大负担。目前的自身免疫性疾病治疗方法包括广泛作用的免疫抑制剂,这些药物缺乏疾病特异性,疗效有限,并带来不良的副作用。此外,在自身免疫性疾病进展过程中,用于恢复器官和组织损伤的治疗方法非常有限。细胞疗法是治疗领域的一个新兴领域,有可能解决自身免疫性疾病的免疫功能障碍以及自身免疫性疾病损伤的组织和器官系统问题。在这篇综述中,我们讨论了常见自身免疫性疾病的发病机制以及细胞疗法在以下两个方面的最新进展:(1)再生或替代自身免疫性疾病损伤的组织,(2)消除自身免疫中的病理性免疫反应。最后,我们讨论了将细胞产品转化为临床应用的关键注意事项。